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Abstract Breast cancer is one of the most common
causes of cancer-related deaths in women. The estrogen
receptor (ERa) is well known for having growth promoting
effects in breast cancer. Recently, we have identified DC-
SCRIPT (ZNF366) as a co-suppressor of ERa and as a
strong and independent prognostic marker in ESR1 (ERa
gene)-positive breast cancer patients. In this study, we
further investigated the molecular mechanism on how DC-
SCRIPT inhibits breast cancer cell growth. DC-SCRIPT
mRNA levels from 190 primary ESR1-positive breast tu-
mors were related to global gene expression, followed by
gene ontology and pathway analysis. The effect of DC-
SCRIPT on breast cancer cell growth and cell cycle arrest
was investigated using novel DC-SCRIPT-inducible MCF7
breast cancer cell lines. Genome-wide expression profiling
of DC-SCRIPT-expressing MCF7 cells was performed to
investigate the effect of DC-SCRIPT on cell cycle-related
gene expression. Findings were validated by real-time PCR
in a cohort of 1,132 ESR1-positive breast cancer patients.
In the primary ESR1-positive breast tumors, DC-SCRIPT
expression negatively correlated with several cell cycle
gene ontologies and pathways. DC-SCRIPT expression
strongly reduced breast cancer cell growth in vitro, breast
tumor growth in vivo, and induced cell cycle arrest. In
addition, in the presence of DC-SCRIPT, multiple cell
cycles related genes were differentially expressed includ-
ing the tumor suppressor gene CDKN2B. Moreover, in
1,132 primary ESR1-positive breast tumors, DC-SCRIPT
expression also correlated with CDKN2B expression. Col-
lectively, these data show that DC-SCRIPT acts as a novel
regulator of CDKN2B and induces cell cycle arrest in
ESR1-positive breast cancer cells.
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List of abbreviations
CDK Cyclin-dependent protein kinase
cFCS Charcoal stripped FCS
DC Dendritic cell
DC-SCRIPT Dendritic cell specific transcript
ERa Estrogen receptor alpha
ESR1 Estrogen receptor 1
FCS Fetal calf serum
MCF7EV MCF7 empty vector control clone
MCF7SC MCF7 DC-SCRIPT-inducible clone
NR Nuclear receptors
PPAR Peroxisome proliferator-activator receptor
PR Progesterone receptor
RAR Retinoic acid receptor
RT-qPCR Quantitative reverse transcriptase PCR
ZNF366 Zinc finger protein 366
Introduction
Breast cancer is the second most common malignancy in
women, affecting one in eight in the US [1]. Improved
knowledge on the molecular basis for breast cancer devel-
opment has led to the identification of prognostic markers,
enabling personalized treatment regimens beneficial for the
patient [2]. Recently, we found that the nuclear receptor co-
regulator dendritic cell specific transcript [DC-SCRIPT, also
known as zinc finger protein 366 (ZNF366)] has statistically
significant prognostic value for patients with estrogen re-
ceptor alpha (ERa)-positive and/or progesterone receptor
(PR)-positive tumors [3, 4]. It was shown that high DC-
SCRIPT mRNA expression represents a solid prognostic
marker as it predicts—independently of current clinical
prognostic markers such as age, menopausal status, grade,
tumor size and receptor status, increased disease-free,
metastasis-free, and overall survival in patients who did not
receive any adjuvant systemic treatment [3, 4]. Yet, little is
known about the molecular mechanism on how DC-SCRIPT
can inhibit breast cancer progression.
DC-SCRIPT was identified in 2006 and has been shown to
play a versatile role in dendritic cells (DC) as well as cancer
biology [3–11]. Within the immune system, DC-SCRIPT
expression is limited to DCs [1] where it co-regulates Toll-
like receptor-induced cytokine production [6]. In addition,
we and others have shown that DC-SCRIPT acts as a co-
regulator of multiple nuclear receptors (NRs) [3, 7, 8, 11].
NRs are ligand-inducible transcription factors that can di-
rectly bind to DNA and thereby mediate transcription of
genes involved in diverse biological processes, such as
proliferation, differentiation, and metabolism [12–15]. DC-
SCRIPT was shown to interact with: the type I NRs ERa, PR,
glucocorticoid receptor, and the androgen receptor; the type
II NRs peroxisome proliferator-activator receptor (PPAR),
retinoic acid receptor (RAR); and the vitamin D3 receptor [3,
7, 8]. While most NR co-regulators have a distinct activating
or repressing function, co-repressors and co-activators can
occasionally switch roles, depending on the promoter con-
text [16–18]. Interestingly, we have shown that DC-SCRIPT
also acts as a NR co-regulator having both repressing and
activating capabilities [3]. Transcription mediated by the
type I NRs was inhibited by DC-SCRIPT, while the activity
of the type II NRs was enhanced by DC-SCRIPT. Remark-
ably, although several co-regulators exist that have a dual
effect on NR function, to our knowledge, there are currently
no co-regulators known to have such a distinct effect on type
I and type II NR mediated transcription.
In line with the finding that DC-SCRIPT exhibits a re-
pressive activity on the pro-proliferative type I NRs and
enhances the mainly anti-proliferative activity of type II
NRs, DC-SCRIPT expression in breast cancer cells results
in the inhibition of breast cancer cell proliferation [3].
Proliferation of cells is a tightly regulated process to avoid
malignant transformation. Cellular transformation has
often been linked to lack of cell cycle control, and in
general, three regulatory mechanisms are responsible for
cell cycle progression; (1) the production and degradation
of cyclins in oscillating cycles, (2) the (de)-phosphoryla-
tion of cyclin-dependent protein kinases (CDKs) and cy-
clins, and (3) the interaction of different CDK inhibitory
proteins from the INK4 and Cip/Kip protein families with
CDK/cyclin-complexes. While the Cip/Kip family mem-
bers have a wide range of CDK/cyclin-complex specifici-
ties, the INK4 family members more specifically inhibit
CDK/cyclin D complexes, thereby arresting cells in the G1
phase of cell cycle progression. Interestingly, many of the
INK4/Cip/Kip family members have been shown to play an
important role in breast cancer [19–21].
Here, we show that DC-SCRIPT expression in ESR1?
(estrogen receptor 1, gene encoding ERa) breast cancer cells
induces G1 cell cycle arrest and acts as a novel regulator of
the gene CDKN2B encoding the tumor suppressor protein
p15ink4b. Moreover, we show that DC-SCRIPT correlates
with CDKN2B expression in a cohort of 1,132 ESR1? -
positive primary tumors of breast cancer patients.
Methods
Patients
The protocol to study biological markers associated with
disease outcome was approved by the medical ethics com-
mittee of the Erasmus Medical Center Rotterdam, The
Netherlands (MEC 02.953). The study was performed in
accordance with the Code of Conduct of the Federation of
694 Breast Cancer Res Treat (2015) 149:693–703
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Medical Scientific Societies in the Netherlands (www.federa.
org), and consent was not required. This retrospective study
used 1,505 blind-coded freshly frozen primary tumor tissues
of female patients with operable breast cancer from 1978
through 2000. The primary breast tumors were from patients
with detailed clinical follow-up as previously described [4].
Cell culture
The MCF7 cell line expressing rtTA2S-M2 (ATCC, Tet-On
Advanced, Clontech) was cultured in DMEM with glutamax
(Invitrogen), supplemented with 10 % heat-inactivated fetal
calf serum (FCS, Greiner Bio-One), 0.5 % antibiotic–an-
timycotics (Invitrogen), and 100 lg/mL G418 (Gibco) to
select for the rtTA2s-M2 plasmid. Cells transfected with
pTRE reporter constructs (see below) were cultured with
additional hygromycin B (100 lg/mL, Calbiochem).
Generation of DC-SCRIPT inducible MCF7 cells
DC-SCRIPT from pCATCH-DCSCRIPT [5] was cloned in
the multiple cloning site of pTRE-tight (Clontech) vector as
a BamH1/Xba1 insert. pTRE-tight was used as the control
plasmid.
MCF7 cells expressing rtTA2S-M2 were transfected with
pTRE-tight or pTRE-tight-DC-SCRIPT and co-transfected
with a hygromycin B resistance marker using metafectene
according to the manufactures protocol (Biontex). Two days
after transfection the transfected cells were selected with
100 lg/mL hygromycin B and 100 lg/mL G418. After ex-
panding the positively selected cells, single colonies were
picked, expanded, and checked by PCR for complete ge-
nomic incorporation of the correct pTRE-tight vector. Clones
containing the DC-SCRIPT vector were labeled MCF7SC,
and control clones containing the empty vector were labeled
MCF7EV. MCF7SC29, MCF7SC36, MCF7EV16, and
MCF7EV37 were chosen for further studies. DC-SCRIPT
protein expression in these cell lines was validated using
Western blot as previously described [6].
MTT assay
MCF7SC or MCF7EV clones were plated at equal numbers
in the presence of 0 (vehicle), 10, 100, or 1,000 ng/mL
doxycycline at day 0, and medium was refreshed every
second day with fresh doxycycline. Relative cell viability/
proliferation was determined by a MTT-based colorimetric
cell proliferation assay (Sigma) after 5 days of culturing.
Cell cycle distribution
MCF7 inducible cells were cultured with 0 or 100 ng/mL
doxycycline and synchronized using serum starvation for
24 h. Cells were released in 10 % charcoal stripped FCS
(cFCS) ± 10 nM E2 (Sigma) for 20 h, lysed in 1 g/L
sodium-citrate buffer containing 0.1 mg/mL RNase A,
20 lg/mL propidium-iodide, and 0.1 % Triton, and ana-
lyzed for cell cycle distribution using bivariate flow cy-
tometry on a FACSCalibur (BD). FlowJo software
(TreeStar) was used for cell cycle position using the cell
cycle algorithm.
In vivo MCF7SC/EV xenograft model
All animal experiments were approved by the Animal
Experimental Committee of the Radboud UMC and were
performed in accordance with institutional, national and
European guidelines. 6–8-week-old female BALB/c-nude
mice (Janvier Labs) were inoculated orthotopically in the
mammary fat pad with 5 9 106 MCF7SC29 or
MCF7EV16. On the same day, a 60-day-slow release pellet
containing 17b-estradiol (0.72 mg/pellet, Innovative Re-
search of America) was implanted s.c. using a trochar for
small pellet implantation (Innovative Research of Amer-
ica). Upon tumor establishment, mice were treated with
2 mg/mL doxycycline in normal drinking water or vehicle
control. Mice weight was monitored every second day, and
no significant differences were observed between ex-
perimental groups. Tumor size was measured every second
day using a caliper, and volume was calculated as de-
scribed in [22]. Part of the tumor xenografts were snap-
frozen and embedded in OCT embedding matrix (CellPath)
and stained for DC-SCRIPT as previously described [3].
Microarray analysis
Genome-wide expression profiling of treated and untreated
MCF7 cells was performed on a Illumina HumanHT-12 WG-
DASL V4.0 R2 expression BeadChip according to the
manufacturer’s description. For this, total RNA was isolated
by lysing cells cultured in 6-well plates followed by total RNA
isolation with the Quick-RNA MiniPrep kit (zymo research)
and quantified using Nanodrop. Next, 500 ng total RNA was
amplified in the presence of UDG and after hybridization on
the BeadChip scanned on an iScan Reader using the associ-
ated BeadScan software. Scanned data were uploaded into
GenomeStudio software (v2011.1) via the gene expression
module (WG-DASL Assay), after which raw bead informa-
tion was further normalized and analyzed with Lumi R
package [23]. All normalized and non-normalized microarray
data have been submitted to the GEO database (accession
number GSE59995, reviewer link: http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?token=gxsdeysonpuhlep&acc=GSE5
9995 [link will be removed before publication]).
In addition, in clinical breast cancer samples, ZNF366
mRNA levels (measured as described before [4]) were
Breast Cancer Res Treat (2015) 149:693–703 695
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compared with expression data we had available of 190
ESR1-positive LNN breast tumors that were analyzed be-
fore on the Affymetrix oligonucleotide Human U133a
Gene Chips [24–26], GEO accession numbers GSE2034
and GSE5327.
Gene ontology and pathway analysis was conducted
using the Functional Annotation Tool at the DAVID
Bioinformatics Resources [27, 28].
RNA isolation and quantitative reverse transcriptase
PCR (RT-qPCR) of MCF7
Total RNA was isolated and reverse transcribed into cDNA
as described before [6]. mRNA levels for the genes of in-
terest were determined with a CFX96 sequence detection
system (Bio-Rad) with SYBR Green (Roche) as the fluor-
ophore and gene-specific oligonucleotide primers. The
primers for ZNF366 and the reference gene HMBS were
described previously [3]. Other used primers are as follows:
CDK6 (F-CCAGATGGCTCTAACCTCAGT, R-AACTTC
CACGAAAAAGAGGCTT), and CDKN2B (F-CGAGGA
GAACAAGGGCATGC, R-CTGTCGCACCTTCTCCAC
TAG). Reaction mixtures and program conditions were
used that were recommended by the manufacturer (Bio-
Rad). Quantitative PCR data were analyzed with the CFX
Manager software (Bio-Rad) as described before [6], and
mRNA levels were calculated according to the cycle
threshold method [29].
RT-qPCR of patient samples
Tissue processing, RNA isolation, cDNA synthesis, and
quantitative reverse transcriptase polymerase chain reaction
(RT-qPCR) were performed and normalized using the delta
Cq method on the average of 3 reference genes (HMBS
[F-CATGTCTGGTAACGGCAATG, R-GTACGAGGCTT
TCAATGTTG], HPRT1 [F-TATTGTAAT GACCAGTCA
ACAG, R-GGTCCTTTTCACCAGCAAG] and TBP [F-TT
CGGAGAG TTCTGGGATTG, R-ACGAAGTGCAATGG
TCTTTAG) as previously described [4, 30]. Quantification
of target genes was done using the following intron-span-
ning Taqman probe-based gene expressions assays (Applied
BioSystems): CDKN2B, Hs00793225_m1; and ZNF366,
Hs00403536_m1 according the manufacturer’s instructions.
Other primers used to analyze mRNA expression by SYBR
Green based real-time PCR in a Mx3000P Real-Time PCR
System (Agilent) were as follows: CDK6: F-AGGTCTG
GACTTTCTTCATTC, R-CTGGACTGGAGCAAGACTT
C; ESR1: F-ATCCTACCAGACCCT TCAGTG, R-GCCAG
ACGAGACCAATCATC. Samples were grouped in ESR1
negative and positive according the cut off at 0.2 as de-
scribed in [31].
Results
DC-SCRIPT expression in breast cancer patients
negatively correlates with cell cycle genes
Previously, we reported that DC-SCRIPT is a unique NR
modulator and that its mRNA expression is a strong and
independent marker of favorable prognosis in ESR1-posi-
tive breast cancer [3, 4, 7, 8, 11]. To gain further insight
into the functional role of DC-SCRIPT in breast cancer
cells, DC-SCRIPT mRNA levels from 190 primary ESR1-
positive breast tumors [4] was related with the global gene
expression data that was available for these tumors. This
analysis revealed that high DC-SCRIPT mRNA expression
negatively correlated with several cell cycle gene ontolo-
gies and pathways (Table 1). Cell cycle related genes
negatively correlating with DC-SCRIPT mRNA included
CDK2, CCNB1, CCNE2, and E2F1 (Table 2). Intriguingly,
a correlation with cell cycle proteins is precisely what one
would expect of a protein inhibiting the activity of the pro-
proliferative type I NRs ERa and PR and stimulating the
activity of the mainly anti-proliferative NRs RAR and
PPAR [3].
DC-SCRIPT negatively regulates cell growth in breast
cancer cell lines in vitro and in vivo
Previously, we have shown that prolonged (over)expres-
sion of DC-SCRIPT in the estrogen-responsive breast
cancer cell line MCF7 transiently transfected with DC-
SCRIPT resulted in growth inhibition of the DC-SCRIPT
expressing cells [3]. To further validate this finding, the
growth inhibitory effects of DC-SCRIPT were determined
in an additional estrogen-responsive cell line CAMA-1
[32]. In agreement with our previous data on MCF7 cells,
also cell growth of CAMA-1 cells could be inhibited by
DC-SCRIPT expression (Appendix A in supplymentary
material).
So far all cell lines analyzed were found to be essentially
negative for endogenous DC-SCRIPT mRNA expression,
including the above mentioned cell lines and 36 other
breast carcinoma cell lines (data not shown). To circum-
vent the problem of the lack of DC-SCRIPT in cell lines for
functional studies, DC-SCRIPT was cloned in front of the
Tet-responsive promoter construct that becomes activated
upon addition of doxycycline [MCF7 Tet-on advanced cell
line (Clontech)]. Following transfection, multiple-inde-
pendent clones expressing DC-SCRIPT (MCF7SC) upon
stimulation with doxycycline or the empty control con-
struct were isolated (MCF7EV) (data not shown). By
varying the doxycycline concentration the expression
levels of DC-SCRIPT can be varied and tuned toward a
physiological level (Fig. 1a). Relative to its endogenous
696 Breast Cancer Res Treat (2015) 149:693–703
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Table 1 Gene ontology and pathways negatively correlating with DC-SCRIPT expression
Category GO term # of genes % Benjamini p value
GOTERM-BP-FAT Cell cycle 24 16 8.87E-05
GOTERM-BP-FAT DNA metabolic process 23 16 8.94E-07
GOTERM-BP-FAT Cell cycle process 19 13 4.93E-04
GOTERM-BP-FAT Cell cycle phase 18 12 5.10E-05
GOTERM-BP-FAT M phase 17 11 1.60E-05
GOTERM-BP-FAT DNA replication 15 10 9.34E-07
GOTERM-BP-FAT Cell division 14 9 4.76E-04
Database Term # of genes % p value
Reactome Cell cycle mitotic 18 12 3.75E-06
Reactome Cell cycle checkpoints 10 7 6.87E-05
KEGG Cell cycle 8 5 6.64E-04
KEGG Oxidative phosphorylation 8 5 8.40E-04
Genes negatively correlating with DC-SCRIPT expression were used as input for the online Functional Annotation Tool at the DAVID
Bioinformatics Resources (National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; http://david.abcc.
ncifcrf.gov). GO, BBID, Biocarta, KEGG, Panther, and Reactome databases were assayed for affected terms. From the output the top terms that
had a p value \ 0.001 are shown
Table 2 Cell cycle-related genes correlating with DC-SCRIPT mRNA expression in 190 primary ESR1? breast tumor specimens
Gene Spearman’s Rs p value Additional cell cycle-related GO annotation
ARL3 -0.41 ** Cytokinesis
BRCA1 -0.38 ** G2 DNA damage checkpoint
KRT18 -0.37 * –
CDK2 -0.35 * G1/S transition of mitotic cell cycle
MAD2L1 -0.34 * Positive regulation of mitotic cell cycle spindle assembly checkpoint
BUB3 -0.34 * Spindle assembly checkpoint
CCNB1 -0.34 * G2/M transition of mitotic cell cycle
KIF11 -0.33 * Spindle assembly involved in mitosis
ZWINT -0.32 * Mitotic cell cycle checkpoint
E2F1 -0.32 * G1/S transition of mitotic cell cycle
TIMELESS -0.31 * Cell cycle phase transition
RAN -0.31 * Mitotic spindle organization
RAD51C -0.31 * Positive regulation of G2/M transition of mitotic cell cycle
CETN3 -0.31 * Mitotic nuclear division
HCAP-G -0.31 * Mitotic chromosome condensation
CHEK1 -0.31 * DNA damage checkpoint
TUBG1 -0.30 * Meiotic spindle organization
RAD54B -0.30 * Reciprocal meiotic recombination
CKS2 -0.30 * Cyclin-dependent protein serine/threonine kinase regulator activity
CKS1B -0.30 * G1/S transition of mitotic cell cycle
CCNE2 -0.30 * G1/S transition of mitotic cell cycle
DDA3 -0.30 * Positive regulation of cyclin-dependent protein serine/threonine kinase activity
KIF22 -0.29 * Mitotic nuclear division
PRC1 -0.29 * Cytokinesis
Cell cycle-related genes significantly correlating with DC-SCRIPT mRNA expression are shown
** p \ 0.01, * p \ 0.05
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expression levels in DCs, MCF7SC29 cells treated with
100 ng/mL doxycycline show physiological DC-SCRIPT
expression levels. Using 100 ng/mL doxycycline, it was
determined that DC-SCRIPT has a protein half-life of 4 h
following doxycycline withdrawal (Fig. 1b) and that
doxycycline addition every 48 h results in the continuous
expression of DC-SCRIPT in these cells (data not shown).
Using an MTT assay, the effect of DC-SCRIPT expression
on cell viability was assayed (Fig. 1c). Increasing DC-
SCRIPT expression levels affected cell viability in two
independent MCF7SC clones, whereas the viability of
MCF7EV16 was not affected by increasing levels of
doxycycline (Fig. 1c). Similar results were obtained from
actual cell count after 6 days of DC-SCRIPT expression
(Appendix B in supplymentary material).
To investigate the effect of DC-SCRIPT expression on
breast tumor growth in vivo, MCF7SC29 or MCF7EV16
cells were inoculated orthotopically in the mammary fat pad
of female nude mice. Simultaneously, an estradiol slow re-
lease pellet was implanted s.c. to stimulate tumor growth.
4 days after implantation when a palpable tumor was pre-
sent, mice either received normal drinking water or water-
containing 2 mg/mL doxycycline to induce DC-SCRIPT
expression (Fig. 2). Strikingly, mice engrafted with the
MCF7SC29 clone receiving doxycycline had a strongly di-
minished tumor growth compared to mice injected with the
MCF7EV16 clone or mice receiving normal water (Fig. 2a).
In line with this, DC-SCRIPT induction in mice engrafted
with MCF7SC29 extended their overall survival, whereas all
control mice reached their endpoint (700 mm3) before day
60, none of the mice engrafted with MCF7SC29 and re-
ceiving doxycycline reached this size before day 60 (data not
shown). DC-SCRIPT expression in the tumor xenografts was
confirmed by immunohistochemistry (Fig. 2b). Altogether
these data demonstrate that DC-SCRIPT expression in breast
cancer cells represses cell growth in vitro and inhibits breast
tumor growth in vivo.
DC-SCRIPT expression arrests breast cancer cells
in G1
DC-SCRIPT mRNA expression in breast cancer patients
negatively correlated with many cell cycle proteins
(Table 2), suggesting that DC-SCRIPT expression inhibits
cell growth by affecting cell cycle progression. To inves-
tigate this hypothesis the MCF7SC and MCF7EV cells
were synchronized by serum starvation for 24 h and then
released in the presence or absence of estradiol (E2) to
induce cell growth, and subjected to cell cycle analysis
using bivariate flow cytometry. Figure 3 shows that
MCF7SC cells and the MCF7EV cells in the absence of
doxycycline have a similar percentage of the cells in the
G1 phase of the cell cycle. In contrast, DC-SCRIPT ex-
pression in two independent MCF7SC clones (29 and 36)
results in significantly more cells in the G1 phase of the cell
cycle compared to the doxycycline treated MCF7EV16.
These data demonstrate that expression of DC-SCRIPT in
breast carcinoma cells leads to G1 cell cycle arrest.
DC-SCRIPT expression induces expression
of the tumor suppressor CDKN2B and its target CDK6
To obtain further insight into the G1 arrest mediated by DC-
SCRIPT, a global gene profiling of the MCF7SC/EV breast
cancer cell lines in the presence and absence of DC-SCRIPT
was performed. Genes having a low expression level (within
the 1st quartile) were filtered out, to minimize the possibility
for false positive results. For the remaining 20,778 probes,
MCF7SC29 and MCF7SC36 were compared to MCF7EV16
after treatment with doxycycline during 20 h release with 10
α-DC-SCRIPT
α-acn
α-DC-SCRIPT
α-acn
iDC  EV37 │-------------------- SC29 ----------------------- │
0 1 10 50 100 250  500  ng/mL dox
EV16 │-------------------------SC29 ----------------------------- -│
-dox    0hr 1hr 2hr 4hr 6hr   8hr 24hr
(a)
(b)
(c)
Fig. 1 DC-SCRIPT protein expression reduces cell viability in vitro.
a MCF7SC29 was treated with increasing amounts of doxycycline.
Induction of DC-SCRIPT protein expression was determined by
Western blot analysis, and related to the amount of endogenously
expressed DC-SCRIPT in immature DC (iDC). The negative control
(MCF7EV37) treated with 500 ng/mL doxycycline is also shown.
b DC-SCRIPT expression was induced with 100 ng/mL doxycycline
for 16 h in MCF7SC29. Cells were washed to remove the doxycy-
cline and cultured for the indicated time points. DC-SCRIPT protein
expression was determined by Western blot analysis. The negative
control MCF7EV16, is also shown. c MCF7SC clones 29 and 36, and
MCF7EV16 were cultured in the presence of 0, 10, 100, and
1,000 ng/mL doxycycline. Cell viability was measured with the MTT
assay at day 5 (data are expressed as the mean of three
experiments ± SEM). Statistics paired two-tailed student t test)
698 Breast Cancer Res Treat (2015) 149:693–703
123
nM E2. In agreement with DC-SCRIPT expression in breast
tumor specimens, also in the MCF7-DC-SCRIPT inducible
model, multiple cell cycle-related genes are differentially
expressed in the presence of DC-SCRIPT. In total, 22 cell
cycle related genes were regulated more than 1.5 fold by DC-
SCRIPT expression in MCF7 cells (Table 3). Interestingly,
the majority of cell cycle genes were downregulated upon
DC-SCRIPT expression (17 out of 22) which is in line with
the negative correlation between DC-SCRIPT expression
and cell cycle genes from the breast cancer specimens
(Tables 1, 2). Notably, many of the 24 cell cycle genes found
to be negatively correlated with DC-SCRIPT expression in
the primary breast cancer specimens were also negatively
regulated by DC-SCRIPT expression in the MCF7 DC-
SCRIPT inducible system (Appendix C in supplymentary
material). The two highest downregulated genes in the
MCF7 system (MAPK13 and CYP26B1) affect cell cycle by
secondary pathways via MAPK signaling [33] and retinoic
acid metabolism [34, 35], respectively. Interestingly, the two
highest upregulated genes, CDKN2B and CDK6, affect cell
cycle directly and belong to the same pathway regulating G1
cell cycle progression [36]. Both these genes’ positive cor-
relation with DC-SCRIPT expression was confirmed by RT-
qPCR in the MCF7 system (Fig. 4), but both genes could not
be reliably detected on the microarray platform used for the
primary breast tumor specimens. Therefore, the CDKN2B
and CDK6 mRNA expression level was assayed in the breast
cancer cohort by RT-qPCR. Intriguingly, DC-SCRIPT
mRNA expression levels also positively correlated with
CDKN2B and CDK6 in 1,132 ESR1-positive breast cancer
patients and much less in 324 ESR1-negatively breast cancer
patients (Fig. 5; Table 4), which is in line with our previous
data showing that DC-SCRIPT has the strongest prognostic
value in the ESR1-positive tumors [3, 4]. Taken together
these data indicate that DC-SCRIPT expression correlates
with multiple cell cycle related genes in breast cancer tissues
and is involved in the regulation of the expression of the cell
cycle inhibitor CDKN2B and CDK6.
Discussion
DC-SCRIPT expression level has been associated with a
favorable prognosis in breast cancer [3, 4], but the mole-
cular mechanism responsible for this relationship is un-
known. Applying an unbiased transcriptome profiling, we
now report that DC-SCRIPT expression in breast cancer
patients correlates with many cell cycle related genes.
Using a novel DC-SCRIPT-inducible breast cancer cell
line, we further show that DC-SCRIPT expression results
in growth- and cell cycle-arrest both in vitro and in vivo.
Additional transcriptome profiling revealed that the pres-
ence of DC-SCRIPT induces the expression of CDKN2B,
the gene encoding the tumor suppressor protein p15ink4b.
Interestingly, DC-SCRIPT mRNA also positively corre-
lates with CDKN2B expression in 1,132 ESR1-positive
breast cancer patients.
The CDKN2B gene has been shown to be expressed in a
range of breast cancer cell lines and normal mammary
epithelial cell strains [37]. Moreover CDKN2B has previ-
ously been linked to cellular senescence and shown to act
as a tumor suppressor protein [38, 39]. Our data now show
EV16 control tumor SC29 DC-SCRIPT tumor
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Fig. 2 DC-SCRIPT expression diminishes tumor growth in vivo.
5 million MCF7SC29 or MCF7EV16 cells were injected into the
lower mammary fat pad, and 60-day-slow release estradiol pellets
(dose: 0.72 mg/pellet) were implanted subcutaneously on the back
between the shoulders of nude mice. After tumor establishment, half
the mice in each group were administered 2 mg/mL doxycycline in
the drinking water throughout the duration of the experiment. a Tumor
growth curves of the MCF7 xenografts. Data are expressed as
mean ± SEM and are the representative out of three experiments
(statistics unpaired two-tailed student t test assuming unequal
variance, n = 4 mice/group). b Immunohistochemistry of tumor
xenograft biopsies. *p \ 0.05, **p \ 0.01
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that DC-SCRIPT expression in breast cancer cells induces
G1 cell cycle arrest and enhances CDKN2B expression,
suggesting that DC-SCRIPT inhibits breast cancer cell
growth at least in part via CDKN2B up regulation.
How DC-SCRIPT regulates CDKN2B expression is
currently unknown. Interestingly, another zinc-finger pro-
tein ZNF217 has also been shown to regulate CDKN2B
expression. ZNF217 inhibits CDKN2B expression by
binding to the CDKN2B promoter, when present in a large
multi-protein complex consisting of e.g., CtBP1 and
HDAC1/2 [40, 41]. DC-SCRIPT is also known to be
present in large multi-protein complexes consisting of
CtBP1, HDAC1/3/6 and depending on the cell context,
different NRs [3, 5, 7, 11]. Another protein that has been
shown to induce CDKN2B expression and cell cycle arrest
in non-transformed cells is TGFb [36, 42, 43]. Possibly via
regulating TGFb expression or activity DC-SCRIPT could
indirectly regulate CDKN2B. Inhibition of the proto-
oncogene and ERa target PIM-1 has also been linked to the
upregulation of CDKN2B and attenuated proliferation of
MCF7 cells [44]. As DC-SCRIPT is known to act as
corepressor protein of ERa [3, 11], DC-SCRIPT may
33.7% G1
32.7% G1
33.4% G1
41.8% G1
29.0% G1
38.7% G1
-dox
+dox
EV16 SC29 SC36
20hr release in 10% cFCS
20hr release in 10% cFCS
+ 10 nM E2
Plate cells 
+/-dox
Day 0
Synchronize by
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Day 1
Release cells in 
cFCS +/- E2
Day 2
Assay cell cycle 
progression
Day 3
(a)
(b)
(c)
Fig. 3 DC-SCRIPT protein expression results in G1 arrest. MCF7SC
clones 29 and 36, and MCF7EV16 were cultured in the absence (-)
or presence (?) of 100 ng/mL doxycycline (dox). The cells were
synchronized using serum starvation for 24 h. Cells were released
with 10 % charcoal-stripped cFCS or 10 % cFCS ? 10 nM E2. 20 h
later cells were checked for their presence in the G1 phase of the cell
cycle using bivariate flow cytometry. a Schematic representation of
the experiment. b Representative flow cytometry histograms. c Mean
value (±SEM) of four independent experiments. Statistics repeated
measures ANOVA with a Bonferroni post test
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repress the estradiol-mediated expression of PIM-1 and
thereby regulate CDKN2B expression and inhibit breast
cancer cell growth. It will be extremely interesting to in-
vestigate the exact molecular mechanism, using for
example, ChIP-Seq, by which DC-SCRIPT regulates di-
rectly or indirectly CDKN2B expression in breast (cancer)
cells in future studies.
CDKN2B is a specific inhibitor of CDK4 and CDK6, pro-
teins that are important in cell cycle G1 phase progression and
G1/S transition. Upon binding, p15ink4b diminishes cyclin
D-mediated activation of these CDKs [36]. Intriguingly, to-
gether with the DC-SCRIPT-mediated CDKN2B upregula-
tion, we also found CDK6 upregulation. This dual
upregulation of a cell-cycle inhibitor and cell cycle activator
has previously been observed [45] and may represent the
tightly regulated balance of cell cycle proteins present during
cell proliferation. Our data have shown that DC-SCRIPT ex-
pression is associated with many cell cycle regulators in a
MCF7 breast cancer cell line as well as in primary breast
cancer specimens. DC-SCRIPT expression skews the balance
toward G1 arrest, resulting in diminished cell growth in vitro.
Moreover, turning on DC-SCRIPT expression in established
MCF7 breast tumors cells in nude mice strongly inhibits the
outgrowth of these tumor cells in vivo. These data emphasize
the dominant role of DC-SCRIPT in breast cancer cell growth.
Taken together, the data presented in this report
demonstrate that DC-SCRIPT affects breast cancer cell
cycle progression by displaying an effect on multiple cell
Table 3 DC-SCRIPT mediated difference in cell cycle related genes expression in MCF7
Upregulation Downregulation
Gene Fold change by
DC-SCRIPT-
induction
Additional cell cycle-related
GO annotation
Gene Fold change by
DC-SCRIPT-
induction
Additional cell cycle-related GO annotation
CDK6 2.10 G1/S transition of mitotic cell cycle MAPK13 -2.65 –
CDKN2B 1.77 Negative regulation of G1/S
transition of mitotic cell cycle
CYP26B1 -2.41 M phase
PCAF 1.55 Cell cycle arrest GSPT1 -1.72 G1/S transition of mitotic cell cycle
LRRCC1 1.54 Mitotic nuclear division SEPT5 -1.67 Cytokinesis
CCNE1 1.51 G1/S transition of mitotic cell cycle CENPE -1.63 Mitotic chromosome movement toward
spindle pole
PRR5 -1.61 –
NEK2 -1.57 Spindle assembly involved in mitosis
CCNB2 -1.56 G2/M transition of mitotic cell cycle
CDC14A -1.54 –
NEDD9 -1.54 Mitotic nuclear division
CENPA -1.52 Establishment of mitotic spindle orientation
TPD52L1 -1.52 G2/M transition of mitotic cell cycle
GTSE1 -1.52 Mitotic G2 phase
CDCA8 -1.51 Mitotic metaphase
DBF4B -1.51 Positive regulation of nuclear cell cycle
DNA replication
CDC25C -1.50 G2/M transition of mitotic cell cycle
BUB1 -1.50 Mitotic spindle assembly checkpoint
Genes with an altered expression level upon DC-SCRIPT-induction in MCF7 cells were assayed for gene ontology association. All genes with a
cell cycle related gene ontology and a DC-SCRIPT-mediated fold change of 1.5 (up and down) are shown
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Fig. 4 Induction of DC-SCRIPT upregulates the tumor suppressor
CDKN2B and its target CDK6 in MCF7s. Purified RNA from
synchronized MCF7SC29, MCF7SC36, and MCF7EV16 cells cul-
tured with 100 ng/mL doxycycline, 20 h after 10 nM E2 stimulation
were assayed by qPCR for a CDKN2B, and b CDK6 expression.
Statistics was done by Mann–Whitney test, *p \ 0.05 (n = 3, error
bars SEM)
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cycle regulators including the upregulation of the cell cycle
inhibitor CDKN2B.
Ultimately, stimulation of DC-SCRIPT expression or
regulation of its downstream targets in ESR1-positive breast
cancer patients may turn out to be a clinically relevant
therapeutic strategy to inhibit breast cancer growth.
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